RA Capital Management
RA Capital Management reported 84 stocks worth $11.5B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are ASND (23.8%), PBLS (6.9%) and RYTM (6.4%). Compared with Q1 2026, the fund opened new positions in ASND, PBLS and COAG, added to ARTV, SLDB and ZLAB, trimmed EWTX, GHRS and GERN and sold out of ASND, DNTH and PRAX.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  ASND Ascendis Pharma A/s | $2.7B | 23.8% | 10.3M | New position | 1 of 8 | |
| 2 |  PBLS Parabilis Medicines Inc Com | $792M | 6.9% | 28.9M | New position | 1 of 8 | |
| 3 |  RYTM Rhythm Pharmaceuticals Inc | $740M | 6.4% | 6.7M | No change | 8 of 8 | |
| 4 |  PCVX Vaxcyte Inc | $667M | 5.8% | 11.5M | No change | 8 of 8 | |
| 5 |  SION Sionna Therapeutics Inc | $436M | 3.8% | 9.9M | No change | 6 of 8 | |
| 6 |  TYRA Tyra Biosciences Inc | $390M | 3.4% | 12.2M | No change | 8 of 8 | |
| 7 |  EWTX Edgewise Therapeutics Inc | $341M | 3.0% | 8.4M | −2M (−20%) | 8 of 8 | |
| 8 |  NAMS Newamsterdam Pharma Company | $324M | 2.8% | 9.6M | No change | 8 of 8 | |
| 9 |  COAG Hemab Therapeutics Hldgs Inc | $287M | 2.5% | 7.8M | New position | 1 of 8 | |
| 10 |  SEPN Septerna Inc | $234M | 2.0% | 7M | No change | 7 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
ASND Ascendis Pharma A/s | $2.4B | 10.3M |
 DNTH Dianthus Therapeutics Inc | $219M | 2.6M |
 PRAX Praxis Precision Medicines I | $120M | 374K |
 SRPT Sarepta Therapeutics Inc | $84.9M | 3.9M |
 SYRE Spyre Therapeutics Inc | $81.8M | 1.6M |
🔒 Free account: see all 18.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →RA Capital Management 13F FAQ
What does RA Capital Management own?
RA Capital Management reported 84 stocks worth $11.5B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are ASND (23.8%), PBLS (6.9%) and RYTM (6.4%). The table above lists every position in the filing (the top 10 without an account).
What did RA Capital Management buy and sell in Q2 2026?
Compared with Q1 2026: 17 new positions, 9 added to, 10 trimmed and 18 sold out. New positions include ASND, PBLS and COAG. It sold all of ASND, DNTH and PRAX.
When will RA Capital Management file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is RA Capital Management's portfolio worth?
The Q2 2026 filing reports $11.5B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.